COX-2 Inhibitors No Longer The Pits: Tragara's Apricoxib Shows Potential In Phase II APRICOT-L Lung Cancer Trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Tragara Pharmaceuticals, Inc. may have found a beneficial use for a COX-2 inhibitor in oncology, and it involves using a urine test, not a biopsy, to match non-small cell lung cancer patients with the therapy.
You may also be interested in...
NSCLC Market Snapshot: Promising Biomarkers, Testing Challenges
Biomarker-guided targeted therapy has become a standard approach to oncology R&D, but few new targeted drugs have reached the market for lung cancer. A new wave of research could change that, and improve the outlook for lung cancer treatment.
Pfizer Pulls Celebrex's FAP Indication Quickly After Slow Trial Results
The European Medicines Agency issues a formal review, even though the claim had been withdrawn, in order to discourage off-label use.
Will COX-2 + Biomarker = Success? Novartis Tests the Frontiers of Companion Diagnostics
A new genetic blood test that identifies patients at risk of liver toxicities may give Joicela (formerly Prexige) new life.